Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    IgY | Cystic Fibrosis
Previous Study | Return to List | Next Study

Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (PsAer-IgY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01455675
Recruitment Status : Completed
First Posted : October 20, 2011
Last Update Posted : July 6, 2017
Sponsor:
Information provided by (Responsible Party):
Mukoviszidose Institut gGmbH

Tracking Information
First Submitted Date  ICMJE October 18, 2011
First Posted Date  ICMJE October 20, 2011
Last Update Posted Date July 6, 2017
Study Start Date  ICMJE October 2011
Actual Primary Completion Date June 27, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 19, 2011)
Time from start of treatment (=Day 0) to the first recurrence of PA (Pseudomonas aeruginosa) in the sputum or throat cough swab or endolaryngeal suction [ Time Frame: max. 24 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 19, 2011)
  • • Change in FEV 1.0 from day 0 to each visit [ Time Frame: max. 24 months ]
  • • Change in BMI from day 0 to each visit [ Time Frame: max. 24 months ]
  • • Number of exacerbations [ Time Frame: max. 24 months ]
  • • Number of days of illness in hospital and at home, i.e. out of school or work [ Time Frame: max. 24 months ]
  • • Control of use of antibiotics, especially anti-pseudomonas antibiotics -measured as days with antibiotic treatment [ Time Frame: max. 24 months ]
  • • Change in values of serologic tests for PA precipitins from day 0 to each visit (if applicable) [ Time Frame: max. 24 months ]
  • • Good tolerability and comparable number and quality of adverse events like placebo group [ Time Frame: max. 24 months ]
  • • Sputum or throat cough swab or endolaryngeal suction cultures for bacteria and fungi [ Time Frame: max. 24 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients
Official Title  ICMJE Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients
Brief Summary The purpose of this study is to prolong the time to reinfection with Pseudomonas aeruginosa after successfully treated acute or intermittent infection.
Detailed Description

This is a double -blind, placebo controlled study in which the investigational drug and the reference placebo group are gargled and swallowed. 70 ml IgY/ placebo solution is gargled every night for two minutes (for maximal 24 months) The design will include the recruitment of 144 patients randomized in two groups (72 per treatment group) In order to compensate for dropouts (i.e. patients dropping out prior to 24 months without having an event) the total sample size was planned to be approximately 180 (i.e. ~20 % dropout rate). After the actual drop-out rate has been low throughout the study, only 144 plus approx. 10% potential drop-outs were included into the study.

During the two years of treatment, subjects will be examined at the clinic every 3 months regarding safety and efficacy of the medication.

For more information please see www.impactt.eu The IMPACTT Project is funded by EU within the Framework 7 Program. PsAer-IgY Studies is part of IMPACTT Project (Workpackage 2).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Condition  ICMJE Cystic Fibrosis
Intervention  ICMJE
  • Drug: IgY
    Avian polyclonal anti-pseudomonas antibodies (IgY)
    Other Name: PsAer-IgY
  • Drug: Placebo
    Placebo, 70 ml gargling solution, once daily
Study Arms  ICMJE
  • Experimental: IgY, gargling solution
    Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
    Intervention: Drug: IgY
  • Placebo Comparator: Placebo, gargling solution
    70 ml gargling solution without antibodies, once daily
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 4, 2015)
164
Original Estimated Enrollment  ICMJE
 (submitted: October 19, 2011)
180
Actual Study Completion Date  ICMJE June 27, 2017
Actual Primary Completion Date June 27, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • CF patients diagnosed according to specific clinical features and either a positive sweat chloride in double proofs or presence of disease-associated CFTR mutations in both alleles
  • Males and females 5 years of age and above (being able to gargle)
  • CF patients having a FEV1 value between 50% and 130% of predicted value (according to Knudson formula)
  • CF patients who have had one to several sputum or throat cough swabs or endolaryngeal suction cultures positive for PA within the last three years and for whom PA has been successfully eradicated.
  • Sputum / throat cough swab/ endolaryngeal suction culture negative for PA and other gram-negative bacteria on study entry.
  • Patients and/ or their legal representative who are willing and able to give informed consent/ assent to participate in the study after thorough information
  • Subjects of child bearing potential and who are sexually active must meet the contraception requirements (i.e. oral or injectable contraceptives, intrauterine devices, double-barrier method, contraceptive patch, male partner sterilization or condoms).

Exclusion Criteria:

  • Microbiologic or serologic evidence of chronic infection with PA. Definition of chronic PA infection: Three cultures (sputum or throat cough swabs or endolaryngeal suction) have been positive for PA for 6 consecutive months (at least 3 cultures have to be taken) or more, .
  • Patients, who have positive sputum culture or throat cough swab or endolaryngeal suction culture for gram-negative bacteria, such as PA, S. maltophilia, B. cepacia, A. xylosoxidans (eradication before entry in study is possible), Patients, who have positive sputum culture or throat cough swab or endolaryngeal suction culture for atypical Mycobacteria and / or Aspergillus fumigates, associated with clinical symptoms that may necessitate specific treatment.
  • History of allergy/hypersensitivity to hens' egg proteins (including medication allergy) that is deemed relevant to the trial by the investigator. "Relevance" in this context refers to any increased risk of hypersensitivity reaction to trial medication.
  • Patient with a known relevant substance abuse, including alcohol or drug abuse.
  • Start of a new concomitant or chronic medication for CF within 4 weeks before inclusion.
  • Clinically relevant diseases or medical conditions other than CF or CF-related conditions that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data. This includes, but is not limited to, significant hematological, hepatic, renal, cardiovascular, and neurological diseases (diabetic patients may participate if their disease is under good control prior to inclusion).
  • Participation in another study with an investigational drug within one month or 6 half-lives (whichever is greater) preceding the inclusion.
  • The patient is an employee of the investigator or the institution with direct involvement in the trial or other trials under the direction of the investigator or their members.
  • Patients who are pregnant cannot be included into the study. This will be tested at inclusion visit with a urine pregnancy test (in female patients older than 10 years with secondary sexual characteristics)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 5 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Belgium,   Germany,   Hungary,   Ireland,   Italy,   Poland,   Spain,   Sweden
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01455675
Other Study ID Numbers  ICMJE PsAer-IgY
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Mukoviszidose Institut gGmbH
Study Sponsor  ICMJE Mukoviszidose Institut gGmbH
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Antje Schuster, Prof. Dr. Universitätsklinikum Düsseldorf
PRS Account Mukoviszidose Institut gGmbH
Verification Date July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP